Business Development
Proprietary Drug
Discovery Program
Asset Development Plan
Biophagy is screening its patented compounds in a variety of important disease indications to evaluate structure-activity relationships and develop leads. Initial work has focused on in vitro models; however, we expect to advance to in vivo evaluation followed by lead identification and pre-clinical evaluation. Biophagy is seeking partnerships with investors or other pharmaceutical companies to help advance these goals.
Acquiring IP
Biophagy’s corporate mission includes the acquisition of additional intellectual property in autophagy. The company will acquire unique screening libraries with autophagy potential plus patents and technologies covering in vitro and in vivo screens.
Partnering Expectations
Biophagy will partner with a large/mid-sized pharma company having expertise in one or more of its targeted disease areas. Together we will develop Biophagy’s lead(s) into pharmaceutical products, either as primary therapies or therapeutic adjuncts to the standard of care.
CellWatch™ (Patent Pending): An OTC/DTC Product for Autophagy Stimulation
and Measurement
Asset Development Plan
Biophagy is developing an OTC/DTC product focusing exclusively on autophagy stimulation for general health and longevity. This includes a rationally designed combination of autophagy stimulants partnered with a unique method of measuring autophagy in an individual. CellWatch™ subscription customers will be able to monitor the product’s effect on their own individual physiology. See CellWatch™
Acquiring IP
Biophagy has filed patents to protect the concept of mixing specific autophagy drugs coupled with a unique method of measuring autophagy in an individual. Additional IP is also being pursued in this area.
Partnering Expectations
Biophagy is seeking investors interested in the rapidly growing OTC/DTC supplements market, especially in general health enhancement, increasing longevity, and alleviating the symptoms of aging.
CellWatch™ (Patent Pending): An OTC/DTC Product for Autophagy Stimulation and Measurement
Asset Development Plan
Biophagy is developing an OTC/DTC product that will focus exclusively on autophagy stimulation for general health and longevity. This product includes a rationally designed combination of autophagy stimulants partnered with a unique method of measuring autophagy in an individual. CellWatch™ subscription customers will be able to monitor the product’s effect on their own individual physiology. See CellWatch™
Acquiring IP
Biophagy has filed patents to protect the concept of mixing specific autophagy drugs coupled with a unique method of measuring autophagy in an individual. Additional IP is also being pursued in this area.
Partnering Expectations
Biophagy is seeking investors interested in the rapidly growing OTC/DTC supplements market, especially in general health enhancement, increasing longevity, and alleviating the symptoms of aging.